Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Voyager Therapeutics Inc

Healthcare US VYGR

3.56USD
-0.04(1.11%)

Last update at 2026-06-04T17:54:00Z

Day Range

3.543.75
LowHigh

52 Week Range

6.0614.07
LowHigh

Fundamentals

  • Previous Close 3.60
  • Market Cap449.29M
  • Volume327840
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.49100M
  • Revenue TTM119.04M
  • Revenue Per Share TTM2.52
  • Gross Profit TTM -19.85700M
  • Diluted EPS TTM-0.17

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax 133.74M -46.39200M -71.19700M 36.74M -43.59700M
Minority interest - - - - -
Net income 132.33M -46.40800M -66.03200M 36.74M -40.83200M
Selling general administrative 35.82M 30.98M 37.25M 34.99M 36.34M
Selling and marketing expenses - - - - -
Gross profit 245.57M 40.91M 37.41M 62.38M 104.39M
Reconciled depreciation 4.44M 6.19M 5.17M 3.82M 2.77M
Ebit 122.01M -50.83700M -73.61800M 27.38M -51.67900M
Ebitda 126.45M -44.64600M -68.45300M 31.20M -48.91400M
Depreciation and amortization 4.44M 6.19M 5.17M 3.82M 2.77M
Non operating income net other - 2.65M 2.81M 7.70M 1.62M
Operating income 122.01M -50.83700M -73.61800M 27.38M -51.67900M
Other operating expenses 127.99M 91.74M 111.03M 143.74M 156.07M
Interest expense - 1.79M 0.39M 0.00000M 0.00000M
Tax provision 1.41M 0.02M 0.00000M 0.00000M 0.00000M
Interest income - - 0.33M 1.66M 6.46M
Net interest income 11.72M 1.79M -0.39000M 1.66M 6.46M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.41M 0.02M -5.16500M -1.65900M -2.76500M
Total revenue 250.01M 40.91M 37.41M 171.13M 104.39M
Total operating expenses 123.55M 91.74M 111.03M 143.74M 156.07M
Cost of revenue 4.44M 6.19M 73.79M 108.75M 119.73M
Total other income expense net 11.72M 4.45M 2.42M 9.36M 8.08M
Discontinued operations - - - - -
Net income from continuing ops 132.33M -46.40800M -71.19700M 36.74M -43.59700M
Net income applicable to common shares - -46.40800M -71.19700M 36.74M -43.59700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 351.28M 159.36M 193.85M 261.58M 354.76M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.35M 4.23M 1.70M 1.57M 1.95M
Total liab 114.96M 100.34M 98.80M 107.26M 255.25M
Total stockholder equity 236.32M 59.02M 95.06M 154.32M 99.51M
Deferred long term liab - - - - -
Other current liab 16.82M 1.37M 2.74M 14.21M 21.52M
Common stock 0.04M 0.04M 0.04M 0.04M 0.04M
Capital stock 0.04M 0.04M 0.04M 0.04M 0.04M
Retained earnings -261.18200M -393.51200M -347.10400M -275.90700M -312.64800M
Other liab - 7.45M 9.21M 37.09M 148.26M
Good will - - - - -
Other assets 0.00000M 1.51M 1.78M 2.32M 1.72M
Cash 68.80M 98.96M 117.43M 104.44M 86.04M
Cash and equivalents - - - - -
Total current liabilities 64.51M 72.59M 50.98M 26.77M 76.01M
Current deferred revenue 42.88M 65.83M 42.10M 7.73M 47.23M
Net debt -48.50900M -75.83300M -73.25400M -56.83300M -51.87400M
Short term debt 3.20M 2.83M 5.57M 4.20M 3.19M
Short long term debt - - - - -
Short long term debt total 20.29M 23.13M 44.18M 47.61M 34.17M
Other stockholder equity 497.51M 452.71M 442.26M 430.32M 412.23M
Property plant equipment - 17.86M 21.92M 25.43M 46.46M
Total current assets 319.68M 124.50M 136.70M 197.77M 304.66M
Long term investments - - - 0.00000M 1.92M
Net tangible assets - 59.02M 95.06M 154.32M 99.51M
Short term investments 162.07M 19.89M 15.11M 76.70M 195.49M
Net receivables 84.45M 0.64M 0.75M 8.11M 18.97M
Long term debt - - - - -
Inventory 0.00000M 0.78M 1.71M 6.95M 2.20M
Accounts payable 1.60M 2.57M 0.57M 0.63M 4.07M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.04800M -0.21900M -0.13800M -0.13400M -0.10400M
Additional paid in capital - - - - -
Common stock total equity - 0.04M 0.04M 0.04M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - -393.51200M -347.10400M -275.90700M -312.64800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M 1.51M 1.78M 2.32M 1.72M
Deferred long term asset charges - - - - -
Non current assets total 31.60M 34.86M 57.16M 63.81M 50.10M
Capital lease obligations 20.29M 23.13M 44.18M 47.61M 34.17M
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -141.64300M -4.84800M 67.52M 125.09M -82.93100M
Change to liabilities - -1.15600M -3.39500M -9.91600M 14.33M
Total cashflows from investing activities - -7.33900M 65.91M 113.00M -90.47700M
Net borrowings - - - - -
Total cash from financing activities 33.65M 1.11M 0.61M 3.16M 80.99M
Change to operating activities - -5.72700M -2.20500M -0.90900M 13.51M
Net income 132.33M -46.40800M -71.19700M 36.74M -43.59700M
Change in cash -30.15700M -18.73800M 12.99M 19.44M 39.18M
Begin period cash flow 98.96M 119.21M 106.22M 86.78M 47.59M
End period cash flow 68.80M 100.47M 119.21M 106.22M 86.78M
Total cash from operating activities 77.92M -12.50900M -53.52500M -96.71600M 48.67M
Issuance of capital stock 31.12M 0.00000M 0.00000M 0.00000M 77.62M
Depreciation 4.44M 6.19M 5.17M 3.82M 2.77M
Other cashflows from investing activities - - - - 0.17M
Dividends paid - - - - -
Change to inventory - - -2.20500M -0.90900M 13.51M
Change to account receivables -83.23400M 0.47M 7.28M 10.48M -18.49600M
Sale purchase of stock - 0.48M 0.58M 0.84M 0.66M
Other cashflows from financing activities 33.65M 1.11M -0.58400M -0.84400M 2.71M
Change to netincome - 9.72M 11.32M 14.93M 14.03M
Capital expenditures 3.26M 2.49M 1.61M 12.10M 7.72M
Change receivables - - - - -
Cash flows other operating - 19.16M 4.23M -142.31900M 64.73M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -18.73800M 12.99M 19.44M 39.18M
Change in working capital -66.55700M 20.47M 3.29M -144.53700M 78.44M
Stock based compensation 11.15M 9.34M 11.32M 14.93M 15.64M
Other non cash items 100.78M -2.10700M -2.46000M -7.69800M -0.99600M
Free cash flow 74.66M -15.00000M -55.13400M -108.81300M 40.95M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VYGR
Voyager Therapeutics Inc		 -0.04 1.11% 3.56 - - 1.83 1.94 0.99 1.95
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Voyager Therapeutics Inc

75 Hayden Avenue, Lexington, MA, United States, 02421

Key Executives

Name Title Year Born
Mr. Robert W. Hesslein Sr. VP & Gen. Counsel 1953
Mr. G. Andre Turenne Advisor 1974
Dr. Alfred W. Sandrock Jr., M.D., Ph.D. Pres, CEO & Director 1958
Dr. Krystof Bankiewicz M.D., Ph.D. Founder NA
Dr. Guangping Gao Ph.D. Founder NA
Dr. Mark A. Kay M.D., Ph.D. Founder 1958
Dr. Phillip D. Zamore Founder NA
Mr. Peter P. Pfreundschuh CPA Chief Financial Officer 1969
Ms. Robin Swartz Chief Operating Officer 1971
Mr. Todd Carter Ph.D. Chief Science Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.